Q3 2025 · 13F-HR
Avoro Capital Advisors LLCholdings as filed
Filed 2025-11-14 · accession 0001104659-25-111932
$7.74B
Reported value
32
Positions
2025-09-30
Period end
The Brief · Avoro Capital Advisors LLC · Q3 2025
AI · grounded in 13F
Avoro Capital Advisors LLC established a new position in ASCENDIS PHARMA ASNDUSD valued at $1.02B. The fund also initiated new stakes in UNITED THERAPEUTICS CORP UTHR for $852.2M and MADRIGAL PHARMACEUTICALS INC MDGL for $840.7M. Additional new positions include ARGENX SE ARGX at $730.2M and KRYSTAL BIOTECH INC KRYS at $490.4M. Total assets under management stand at $7.74B across 30 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04351P101 | ASNDUSD | ASCENDIS PHARMA | $1.02B | 13.1% | 5,110,000 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $847.7M | 11.0% | 2,022,222 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $840.7M | 10.9% | 1,833,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $730.2M | 9.44% | 990,000 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $490.4M | 6.34% | 2,777,777 | Common | SOLE |
| 04280A100 | ARWR | ARROWHEAD PHARMACEUTICALS INC. | $375.9M | 4.86% | 10,900,000 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $359.4M | 4.65% | 6,350,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $333.5M | 4.31% | 3,542,500 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $333.1M | 4.31% | 7,645,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC. | $276.6M | 3.58% | 12,222,222 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $262.1M | 3.39% | 10,808,080 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $259.4M | 3.35% | 4,444,444 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $216.8M | 2.80% | 5,400,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $187.8M | 2.43% | 3,955,555 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $180.5M | 2.33% | 6,210,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $174.3M | 2.25% | 2,577,777 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC. | $144.4M | 1.87% | 5,155,555 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $122.2M | 1.58% | 2,555,555 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $119.8M | 1.55% | 10,250,000 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC. | $118.4M | 1.53% | 15,025,000 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $93.9M | 1.21% | 6,387,790 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $71.0M | 0.92% | 21,700,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $67.2M | 0.87% | 2,240,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $25.6M | 0.33% | 1,333,340 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $25.2M | 0.33% | 1,337,500 | Common | SOLE |
| 56400P706 | MNKD | MANNKIND CORP | $24.0M | 0.31% | 4,468,877 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $14.3M | 0.19% | 2,000,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $9.5M | 0.12% | 1,250,000 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $5.4M | 0.07% | 2,849,402 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $4.6M | 0.06% | 545,000 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $4.4M | 0.06% | 200,000 | CALL | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC. | $2.2M | 0.03% | 250,000 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.